Travis T Wager

This inventor holds 24 USPTO granted patents and 5 published patent applications, plus 11 CIPO patents and 17 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Pfizer Corporation. Active years: 2006-2024.

USPTO Granted Patents = 24 (Patent Applications = 5)

% Patents Active = 66.7

CIPO Patents = 11 (Patent Applications = 9)

EPO Patents = 17 (Patent Applications = 19)

Average Co-Inventor Count = 3.4

ph-index = 5

Forward Citations = 82(Granted Patents)

Location History:

New London, CT (US) (2006 - 2013)
Brookline, MA (US) (2015 - 2024)

Company Filing History:

24 out of 4,486

Pfizer Corporation

patents

Years Active: 2006-2024

Loading Chart...

Areas of Expertise:

Phosphodiesterase Inhibitors

Dopamine D3 Ligands

LRRK2 Inhibitors

Imidazoquinoline Derivatives

Casein Kinase Inhibitors

Histamine-3 Receptor Antagonists

Pyrazolopyrimidine Compounds

GSK-3 Inhibitors

NK1 Antagonists

Pyrrolo Compounds

Toluene Sulfonic Acid Salt

Pharmaceutical Compositions

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12049465 - Tricyclic compounds and their use as phosphodiesterase inhibitors (2024-07-30),

2. 11472805 - Tricyclic compounds and their use as phosphodiesterase inhibitors (2022-10-18),

3. 11390623 - 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands (2022-07-19),

4. 11312713 - Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors (2022-04-26),

5. 11161844 - Cyclic substituted imidazo[4,5-c]quinoline derivatives (2021-11-02),

6. 10738063 - 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds (2020-08-11),

7. 10590128 - 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands (2020-03-17),

8. 10323042 - 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds (2019-06-18),

9. 10131669 - Pyrazolopyrimidine compounds (2018-11-20),

10. 10039753 - Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors (2018-08-07),

11. 9695171 - 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors (2017-07-04),

12. 9642855 - Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors (2017-05-09),

13. 9156845 - 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors (2015-10-13),

14. 8536164 - Fused pyridine compounds as casein kinase inhibitors (2013-09-17),

15. 8518944 - Compounds as casein kinase inhibitors (2013-08-27),

Title: The Inventive Mind of Travis T. Wager

Introduction:

Travis T. Wager is a prolific inventor based in Brookline, MA (US), with an impressive track record of 23 patents to his name. His innovative spirit and dedication to advancing pharmaceutical compounds have solidified his reputation in the field of medical research and development.

Latest Patents:

One of Travis T. Wager's latest patents involves tricyclic compounds and their use as phosphodiesterase inhibitors. These compounds, represented by Formula I, have shown promising potential in the realm of pharmaceutical compositions for various treatments. Additionally, his patent on 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands highlights his focus on treating D3-mediated disorders such as substance addiction, schizophrenia, cognitive impairment, Parkinson's disease, and more.

Career Highlights:

Travis T. Wager is currently a valuable asset at Pfizer Corporation, a renowned pharmaceutical company known for its groundbreaking research and development efforts. His contributions to Pfizer's innovative projects have propelled the company forward in the realm of medical advancements.

Collaborations:

In his professional journey, Travis T. Wager has had the pleasure of collaborating with esteemed colleagues such as Patrick Robert Verhoest and Jaclyn Louise Henderson. Their combined expertise and dedication to excellence have resulted in successful teamwork on various projects within the pharmaceutical industry.

Conclusion:

Travis T. Wager stands as a shining example of an inventor whose dedication to scientific innovation has led to numerous breakthroughs in the realm of pharmaceuticals. His impressive patent portfolio and collaborative spirit underscore his invaluable contributions to the field of medical research.